Faith
Abortion Industry Pushes Profit Over Life, Korean Bioethics Panel Warns
A recent bioethics colloquium in Seoul exposed how the sacred gift of life is being reduced to a global commodity by pharmaceutical giants.
Dr. Jang Ji-young warned that medication abortion has shifted from an ethical issue into a complex, profit-driven economic system.
This industrial transformation prioritizes corporate expansion over the health of women and the sanctity of the womb.
The shift toward chemical procedures allows companies to bypass medical oversight while maximizing margins on low-cost drugs.
“Abortion was once a matter of personal belief, choice and bioethics. Now it has become a composite economic structure combining public funding and commercial profit.”
Faith Facts
- The global medication abortion market is projected to reach $8 billion by 2035 as corporations leverage telemedicine for expansion.
- Manufacturing costs for abortion pills are as low as $1, yet patients are often charged over $500 for the life-ending drugs.
- Data analysis shows complication rates for chemical abortions may be as high as 10.9%, despite claims of safety from industry advocates.
As South Korea faces legislative changes, believers must pray for policies that protect the unborn and resist the commercialization of death.
True healthcare must always prioritize the preservation of life and the moral integrity of the medical profession.